Skip to main content
TipRanks
Go Ultimate75% OFF

MEDIQON Group AG (CHG) AI Stock Analysis

1 Followers
DE:CHG

MEDIQON Group AG

(XETRA:CHG)

Select Model
Rating:39Underperform
Price Target:EUR 40.00â–¼(-8.05% Downside)
Action:downgraded
Date:10/01/26

The score is dominated by deteriorating fundamentals: MEDIQON has never been profitable, and FY2025 saw negative gross profit, a -€50M EBIT, and a net loss widening to -€29.6M, while total debt tripled to €247.9M against €224M of equity. Positive operating (€8.7M) and free cash flow (€7.0M) provide some reassurance that the acquired businesses generate cash, but the amounts are small relative to the debt load and are trending lower. Technicals add further caution, with the stock below its 20- and 50-day averages and a negative MACD, though deeply oversold RSI and Stochastic readings and price holding above the 100- and 200-day averages leave room for a near-term rebound. Valuation offers no support given negative earnings and no dividend. Overall, this is a high-risk, acquisition-driven growth story that has yet to demonstrate sustainable profitability.

Positive Factors
Strong revenue growthSustained and accelerating revenue growth indicates expanding commercial activity and market reach. If the company can convert this scale into healthier economics, the larger revenue base could support operating leverage, stronger customer relationships, and improved long-term earnings capacity.
Negative Factors
Severe profitability deteriorationThe shift from a normal gross-profit level in 2024 to negative gross profit and large operating and net losses signals that growth is not currently translating into viable earnings. Persistent losses can constrain reinvestment, weaken financial flexibility, and increase dependence on successful restructuring or integration.

MEDIQON Group AG (CHG) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%30%40%DE:CHG+21.17%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.01B
Dividend Yield
―
Average Volume (3M)
26.07K
Price to Earnings (P/E)
-29.1
Beta (1Y)
0.22
Revenue Growth
63.32%
EPS Growth
-47.16%
Country
Germany
Employees
1,300
Sector
Technology
Sector Strength
61
Industry
Software - Application

MEDIQON Group AG Business Overview & Revenue Model

Company Description

CHAPTERS Group AG, headquartered in Hamburg, Germany, was established in 1998 and rebranded from MEDIQON Group AG in July 2023. The company delivers a broad spectrum of software solutions across the DACH region, catering to numerous industries and ap...

MEDIQON Group AG Financial Statement Overview

Summary

Financials are weak overall. Revenue has scaled impressively to €180.8M (+37.4% YoY) via an acquisition-led roll-up strategy, but the company has never reported positive net income, and FY2025 deteriorated sharply: gross profit turned negative (-€12.2M), EBITDA swung to -€2.4M, EBIT fell to -€50M, and the net loss widened to -€29.6M. The balance sheet is a mixed picture — equity is stable near €224M and assets total €665M, but total debt more than tripled to €247.9M, lifting debt-to-equity to roughly 1.11x. Cash flow is the relative bright spot, with operating cash flow of €8.7M and free cash flow of €7.0M, though both declined year-over-year and the ~3.9% FCF margin is thin relative to the debt load.

Income Statement

25Negative

Balance Sheet

40Negative

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2021Dec 2021
Income Statement
Total Revenue214.95M180.80M110.67M70.77M28.66M42.07M
Gross Profit-5.09M-12.21M47.02M8.38M12.26M6.84M
EBITDA16.44M-2.40M16.35M16.14M7.16M4.82M
Net Income-34.72M-29.65M-11.47M-4.08M-2.27M-5.88M
Balance Sheet
Total Assets671.97M665.02M353.74M223.95M103.55M169.28M
Cash, Cash Equivalents and Short-Term Investments115.41M106.74M58.51M50.84M11.09M26.28M
Total Debt265.58M247.94M73.60M69.35M51.70M62.09M
Total Liabilities389.28M351.45M128.75M99.87M61.71M77.11M
Stockholders Equity203.11M223.87M224.99M126.06M42.57M93.76M
Cash Flow
Free Cash Flow6.92M7.02M6.96M3.81M1.15M3.67M
Operating Cash Flow8.91M8.68M11.47M7.37M2.87M5.69M
Investing Cash Flow-49.57M-103.89M-98.82M-36.34M-47.40M-53.21M
Financing Cash Flow86.39M134.24M89.00M48.15M47.06M58.78M

MEDIQON Group AG Technical Analysis

Technical Analysis SentimentNegative
Last Price43.50

Price Trends

50DMA43.97Negative
100DMA43.36Negative
200DMA37.22Positive

Market Momentum

MACD0.08Positive
RSI41.24Neutral
STOCH15.05Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:CHG, the sentiment is Negative. The current price of 43.50 is below the 20-day moving average (MA) of 46.05, below the 50-day MA of 43.97, and above the 200-day MA of 37.22, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 41.24 is Neutral, neither overbought nor oversold. The STOCH value of 15.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:CHG.

MEDIQON Group AG Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

DE:CHG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:OBSDE:OBS78OutperformEUR 44.32M11.7010.52%2.14%0.88%9.19%
DE:ADN1DE:ADN168NeutralEUR 534.01M20.5513.35%0.95%12.62%91.34%
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
DE:BC8DE:BC860NeutralEUR 4.07B16.4912.00%2.17%7.74%14.82%
DE:A1OSDE:A1OS50NeutralEUR 386.60M-38.61-8.99%1.55%-1.94%-161.38%
DE:CHGDE:CHG39UnderperformEUR 1.08B-29.07-16.26%―63.32%-47.16%

* Technology Sector Average

Performance Comparison

0%50%100%DE:CHGDE:ADN1DE:A1OSDE:BC8DE:OBSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:CHG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:CHGMEDIQON Group AG43.507.6021.17%
DE:ADN1adesso AG76.70-14.90-16.27%
DE:A1OSAll For One Group Se78.0040.51108.07%
DE:BC8Bechtle Aktiengesellschaft32.26-5.46-14.48%
DE:OBSORBIS AG4.76-1.12-19.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 01, 2026